| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1586/ERI.10.63 |
| P698 | PubMed publication ID | 20695746 |
| P2093 | author name string | Tomás Reischig | |
| P2860 | cites work | Renal Ischemia/Reperfusion Injury Activates the Enhancer Domain of the Human Cytomegalovirus Major Immediate Early Promoter | Q58071696 |
| Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants | Q31043979 | ||
| A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation | Q33345650 | ||
| Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. | Q34294829 | ||
| Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. | Q34858442 | ||
| Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. | Q36167258 | ||
| Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? | Q36357628 | ||
| Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies | Q36365992 | ||
| Acceleration of allograft failure by cytomegalovirus | Q36433529 | ||
| The significance of subclinical rejection and the value of protocol biopsies | Q36517003 | ||
| Cytomegalovirus-associated allograft rejection in heart transplant patients | Q36869742 | ||
| Infection in solid-organ transplant recipients | Q37038203 | ||
| The 'indirect' effects of cytomegalovirus infection | Q37618248 | ||
| International consensus guidelines on the management of cytomegalovirus in solid organ transplantation | Q37707986 | ||
| In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. | Q39756225 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein | Q40334600 | ||
| The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients | Q43114684 | ||
| Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients | Q43157244 | ||
| Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? | Q44003429 | ||
| The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients | Q44188441 | ||
| CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. | Q44288723 | ||
| Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching | Q44321475 | ||
| Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial | Q44407642 | ||
| Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients | Q44441505 | ||
| Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipients | Q44667078 | ||
| Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection | Q44729858 | ||
| Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients | Q44800855 | ||
| Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients | Q44800866 | ||
| Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival | Q44939151 | ||
| Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis | Q45021351 | ||
| T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease | Q45040833 | ||
| Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. | Q45881220 | ||
| Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients | Q46618896 | ||
| A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients | Q46654110 | ||
| Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation | Q46764122 | ||
| The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection | Q46986384 | ||
| Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules | Q47272578 | ||
| Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients | Q47862821 | ||
| High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. | Q51960438 | ||
| Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. | Q53346269 | ||
| Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. | Q54587707 | ||
| Rat Cytomegalovirus Infection Interferes with Anti-CD4 mAb-(RIB 5/2) Mediated Tolerance and Induces Chronic Allograft Damage | Q56989355 | ||
| Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study | Q57004259 | ||
| P433 | issue | 8 | |
| P921 | main subject | Cytomegalovirus | Q6946 |
| P304 | page(s) | 903-910 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies | |
| P478 | volume | 8 |
| Q37965695 | Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy |
| Q52891818 | Cytomegalovirus-specific regulatory and effector T cells share TCR clonality--possible relation to repetitive CMV infections. |
| Q44738359 | Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. |
| Q42366690 | Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies. |
| Q36200933 | Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation |
| Q47766934 | Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients |
| Q35051236 | Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. |
| Q38254037 | The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation |
| Q41138391 | Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective |
Search more.